Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Masatoshi Kudo et al.|The Lancet|2023Cited by 514
CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancerPaul A. Cohen, M.L. Friedlander, Andreas Obermair et al.|Annals of Oncology|2025Cited by 0